Author

Arrate Plazaola

Observed names: A Plazaola, A. Plazaola

Observed institutions: Universidad Complutense de Madrid, Novartis (Switzerland), Universitat de València, University of Cambridge, Hospital Universitario La Paz, Cancer Research UK, Hospital de Sant Pau, Hospital Universitari Arnau de Vilanova, Hospital Clínico San Carlos, Hospital General Universitario Morales Meseguer, Althaia, Bristol-Myers Squibb (United States), Hospital de Basurto, Hospital Clínico Universitario de Valencia, Consorci Sanitari de Terrassa, Marqués de Valdecilla University Hospital, Hospital Universitario Fundación Alcorcón, Hospital Universitario 12 De Octubre, Fundación Instituto Valenciano de Oncología, Hospital Virgen de la Salud, Hospital Universitario Miguel Servet, Corporació Sanitària Parc Taulí, Complejo Hospitalario de Jaén, Hospital Universitario de La Princesa, Hospital Del Mar, Donostiako Unibertsitate Ospitalea, Onkologikoa, Hospital Clínico Universitario Virgen de la Victoria, Hospital Virgen de los Lirios, Hospital Universitario Ramón y Cajal, GEICAM – Spanish Breast Cancer Group, Instituto de Investigación Biomédica de Málaga, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad de Navarra

OpenAlex ID: A5087383357

Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study

2012 · E. Alba, L. Calvo, et al. · Annals of Oncology · 233

PDF

Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2 -Negative Breast Cancer—The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial

2018 · Luca Gianni, Mauro Mansutti, et al. · JAMA Oncology · 154

PDF

A Single-Nucleotide Polymorphism in the Aromatase Gene Is Associated with the Efficacy of the Aromatase Inhibitor Letrozole in Advanced Breast Carcinoma

2008 · Ramon Colomer, Mariano Monzo, et al. · Clinical Cancer Research · 121

Predicting response and survival in chemotherapy-treated triple-negative breast cancer

2014 · A Prat, A Lluch, et al. · British Journal of Cancer · 114

PDF

Phase II study of weekly Kahalalide F in patients with advanced malignant melanoma

2009 · Salvador Martín-Algarra, Enrique Espinosa, et al. · European Journal of Cancer · 85

Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study

2015 · Miguel Martín, Amparo Ruiz Simón, et al. · Journal of Clinical Oncology · 76

PDF

Fluorouracil, Doxorubicin, and Cyclophosphamide (FAC) Versus FAC Followed by Weekly Paclitaxel As Adjuvant Therapy for High-Risk, Node-Negative Breast Cancer: Results From the GEICAM/2003-02 Study

2013 · Miguel Martín, Amparo Ruiz, et al. · Journal of Clinical Oncology · 60

PDF

Influence of Timing of Initiation of Adjuvant Chemotherapy Over Survival in Breast Cancer: A Negative Outcome Study by the Spanish Breast Cancer Research Group (GEICAM)

2006 · Carlos Jara Sánchez, Amparo Ruiz, et al. · Breast Cancer Research and Treatment · 58

High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer

2016 · Emilio Alba, Ana Lluch, et al. · The Oncologist · 55

A PAM50-Based Chemoendocrine Score for Hormone Receptor–Positive Breast Cancer with an Intermediate Risk of Relapse

2016 · Aleix Prat, Ana Lluch, et al. · Clinical Cancer Research · 49

PDF

Practical prognostic index for patients with metastatic recurrent breast cancer: retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register

2010 · Javier Puente, Sara López-Tarruella, et al. · Breast Cancer Research and Treatment · 42

Phase II clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neoadjuvant treatment in stages II and IIIA HER2-overexpressing breast cancer patients. GEICAM 2003-03 study

2010 · A. Antón, A. Ruiz, et al. · Annals of Oncology · 37

PDF

Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis

2017 · Miguel Martín, José I. Chacón, et al. · The Oncologist · 22

High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer

2016 · Emilio Alba, Ana Lluch, et al. · The Oncologist · 21

PDF

Probabilistic cost-utility analysis and expected value of perfect information for the Oncotype multigenic test: a discrete event simulation model

2018 · Oliver Ibarrondo, Isabel Álvarez-López, et al. · Gaceta Sanitaria · 16

PDF

ETNA (Evaluating Treatment with Neoadjuvant Abraxane) randomized phase III study comparing neoadjuvant nab-paclitaxel (nab-P) versus paclitaxel (P) both followed by anthracycline regimens in women with HER2-negative high-risk breast cancer: A MICHELANGO study.

2016 · Luca Gianni, Mauro Mansutti, et al. · Journal of Clinical Oncology · 16

Chemotherapy (CT) versus hormone therapy (HT) as neoadjuvant treatment in luminal breast cancer: A multicenter, randomized phase II study (GEICAM/2006-03).

2010 · E. Alba, L. Calvo, et al. · Journal of Clinical Oncology · 14

Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile

2016 · Antonio Gonzzlez-Martin, Emilio Alba, et al. · Current Cancer Drug Targets · 13

Analysis of the changes induced by bevacizumab using a high temporal resolution DCE-MRI as prognostic factors for response to further neoadjuvant chemotherapy

2014 · Jon Etxano, Luis Pina Insausti, et al. · Acta Radiologica · 13

Clinical and economic impact of the 21-gene recurrence score assay in adjuvant therapy decision making in patients with early-stage breast cancer: pooled analysis in 4 Basque Country university hospitals

2018 · Purificación Martínez del Prado, Isabel Alvarez-López, et al. · ClinicoEconomics and Outcomes Research · 12

PDF

Dynamic contrast-enhanced MRI versus 18F-misonidazol-PET/CT to predict pathologic response in bevacizumab-based neoadjuvant therapy in breast cancer.

2012 · Jesus Garcia-Foncillas, Purificación Martinez, et al. · Journal of Clinical Oncology · 11

Preventive treatments for breast cancer: recent developments

2014 · J. E. Alés-Martínez, A. Ruiz, et al. · Clinical & Translational Oncology · 9

PDF

Nabrax: Neoadjuvant therapy of breast cancer with weekly single-agent nab-paclitaxel—Final efficacy and biomarkers analysis of GEICAM 2011-02 trial.

2014 · Miguel Martin, Silvia Antolín, et al. · Journal of Clinical Oncology · 5

Spatial intratumoural heterogeneity in the expression of GIT1 is associated with poor prognostic outcome in oestrogen receptor positive breast cancer patients with synchronous lymph node metastases

2017 · Ibai Goicoechea, Ricardo Rezola, et al. · F1000Research · 3

PDF

Anti-HER2 Therapy Beyond Second-Line for HER2- Positive Metastatic Breast Cancer: A Short Review and Recommendations for Several Clinical Scenarios from a Spanish Expert Panel

2016 · Noelia Martínez-Jañez, Ignacio Chacón, et al. · Breast Care · 3

PDF

Works count: 72

Citation count: 1,279

H-index: 16

I10-index: 21